Appels ouverts › Horizon Europe
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Horizon Europe · HORIZON-MISS-2027-02-CANCER-03
Funds phase 1 and first-in-human clinical trials of biomarker-guided medicines or multi-modal treatments for patients with rare or very rare cancers.
Cet appel est annoncé mais pas encore ouvert. Les dates et les conditions peuvent encore changer.
Quel est l’objet de cet appel ?
The call funds research and innovation projects that run phase 1 clinical trials, including first-in-human trials, of biomarker-guided medicines or multi-modal treatments for rare and very rare cancers. Consortia should involve multidisciplinary stakeholders and health authorities.
Que finance cet appel ?
Background
Patients with rare and very rare cancers often have advanced disease at diagnosis, few treatment options, lower five-year survival and limited access to suitable phase 1 trials.
Scope
Proposals should address all of the following:
- Where still needed, complete preclinical validation of promising biomarker-guided drugs for rare or very rare cancer indications using in vivo, ex vivo and/or in silico models, considering drug repurposing.
- Validate early safety and efficacy of innovative medicines, alone or within multi-modal treatment, in phase 1 trials, including first-in-human and multi-centre trials, considering new trial designs.
- Define primary and secondary endpoints covering safety, efficacy and patient-reported outcomes together with patients and caregivers.
- Disaggregate data by tumour biology, sex, gender, age and other relevant variables, register datasets in the European Health Data Space catalogue and make tools available through the future UNCAN.eu platform.
Expected outcomes
- Patients with rare cancers gain access to promising treatments through follow-up trials or compassionate use programmes.
- Researchers, physicians, start-ups, SMEs, charities and other actors gain access to technologies and medicines for further validation or commercialisation.
- Health authorities and policymakers obtain early safety and efficacy evidence to support further testing of affordable treatments.
Quelles sont les informations clés ?
- Budget du thème
- 24 000 000 €
- Montant minimal par projet
- 7 000 000 €
- Montant maximal par projet
- 9 000 000 €
- Code de l’appel
- HORIZON-MISS-2027-02-CANCER-03
- Programme
- Horizon Europe
- Funder
- European Union, Horizon Europe (Cancer Mission)
- Expected number of projects
- 3
Qui peut candidater à cet appel ?
- Applicants should include proof of advice from regulators on the design of the clinical trial(s).
- Consortia should include an appropriate mix of stakeholders from various disciplines, together with regional and national health authorities.
- Successful proposals will be asked to join the Cancer Mission "Diagnosis and treatment" cluster.
Vérifiez votre éligibilité et la pertinence de votre projet
Dans votre compte gratuit, nous vérifions les conditions d’éligibilité au regard des documents de l’appel pour votre organisation et nous évaluons dans quelle mesure votre projet correspond à cet appel.
Qu’attend-on des propositions ?
- Details of the clinical study(ies) should be provided in the dedicated annex template.
Quelle est la date limite ?
16 septembre 2027 (314 jours)
21 September 2027 (single-stage)
Cet appel vous intéresse ? Résumé rédigé par l’IA à partir des documents officiels de l’appel. Certains détails peuvent différer : consultez la page officielle de l’appel avant de candidater. Lisez les documents officiels de l’appel avant de vous décider. Seul le texte officiel fait foi.
Source : portail Funding & Tenders de l’UE et documents officiels de l’appel. Page officielle de l’appel Dernière mise à jour : 6 octobre 2026.